http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 15 Aug 2024 01:37:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/fi..helsin" idsrc="xmltag.org" >HELSINKI</location></span>, <span class="legendSpanClass"><chron>Aug. 15, 2024</chron></span> /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of <span>Takeda Pharmaceuticals, Inc.</span>, the R&amp;D-driven biopharmaceutical company headquartered in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.</p> <p>Following the completion of in vitro proof of concept studies of a novel plasma-derived therapy formulation, Nanoform will provide non-GMP nanomaterial to Takeda for <i>in vivo </i>studies. The first results of these studies are expected by early 2025.</p> <p>"Direct http://www.streetinsider.com/Press+Releases/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html Thu, 15 Aug 2024 01:37:00 -0400 A.39820687 NANOFH NANOFS O.00610135 http://www.streetinsider.com/Press+Releases/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/fi..helsin" idsrc="xmltag.org" >HELSINKI</location></span>, <span class="legendSpanClass"><chron>Aug. 15, 2024</chron></span> /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of <span>Takeda Pharmaceuticals, Inc.</span>, the R&amp;D-driven biopharmaceutical company headquartered in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.</p> <p>Following the completion of in vitro proof of concept studies of a novel plasma-derived therapy formulation, Nanoform will provide non-GMP nanomaterial to Takeda for <i>in vivo </i>studies. The first results of these studies are expected by early 2025.</p> <p>"Direct http://www.streetinsider.com/Press+Releases/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html Thu, 15 Aug 2024 01:37:00 -0400 A.39820687 NANOFH NANOFS O.00610135 http://www.streetinsider.com/Press+Releases/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/fi..helsin" idsrc="xmltag.org" >HELSINKI</location></span>, <span class="legendSpanClass"><chron>Aug. 15, 2024</chron></span> /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of <span>Takeda Pharmaceuticals, Inc.</span>, the R&amp;D-driven biopharmaceutical company headquartered in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.</p> <p>Following the completion of in vitro proof of concept studies of a novel plasma-derived therapy formulation, Nanoform will provide non-GMP nanomaterial to Takeda for <i>in vivo </i>studies. The first results of these studies are expected by early 2025.</p> <p>"Direct http://www.streetinsider.com/Press+Releases/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html Thu, 15 Aug 2024 01:37:00 -0400 A.39820687 NANOFH NANOFS O.00610135 http://www.streetinsider.com/Press+Releases/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/fi..helsin" idsrc="xmltag.org" >HELSINKI</location></span>, <span class="legendSpanClass"><chron>Aug. 15, 2024</chron></span> /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of <span>Takeda Pharmaceuticals, Inc.</span>, the R&amp;D-driven biopharmaceutical company headquartered in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.</p> <p>Following the completion of in vitro proof of concept studies of a novel plasma-derived therapy formulation, Nanoform will provide non-GMP nanomaterial to Takeda for <i>in vivo </i>studies. The first results of these studies are expected by early 2025.</p> <p>"Direct http://www.streetinsider.com/Press+Releases/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html Thu, 15 Aug 2024 01:37:00 -0400 A.39820687 NANOFH NANOFS O.00610135 http://www.streetinsider.com/PRNewswire/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/fi..helsin" idsrc="xmltag.org" >HELSINKI</location></span>, <span class="legendSpanClass"><chron>Aug. 15, 2024</chron></span> /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of <span>Takeda Pharmaceuticals, Inc.</span>, the R&amp;D-driven biopharmaceutical company headquartered in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.</p> <p>Following the completion of in vitro proof of concept studies of a novel plasma-derived therapy formulation, Nanoform will provide non-GMP nanomaterial to Takeda for <i>in vivo </i>studies. The first results of these studies are expected by early 2025.</p> <p>"Direct http://www.streetinsider.com/PRNewswire/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html Thu, 15 Aug 2024 01:37:00 -0400 A.39820687 NANOFH NANOFS O.00610135 http://www.streetinsider.com/PRNewswire/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/fi..helsin" idsrc="xmltag.org" >HELSINKI</location></span>, <span class="legendSpanClass"><chron>Aug. 15, 2024</chron></span> /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of <span>Takeda Pharmaceuticals, Inc.</span>, the R&amp;D-driven biopharmaceutical company headquartered in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.</p> <p>Following the completion of in vitro proof of concept studies of a novel plasma-derived therapy formulation, Nanoform will provide non-GMP nanomaterial to Takeda for <i>in vivo </i>studies. The first results of these studies are expected by early 2025.</p> <p>"Direct http://www.streetinsider.com/PRNewswire/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html Thu, 15 Aug 2024 01:37:00 -0400 A.39820687 NANOFH NANOFS O.00610135 http://www.streetinsider.com/PRNewswire/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/fi..helsin" idsrc="xmltag.org" >HELSINKI</location></span>, <span class="legendSpanClass"><chron>Aug. 15, 2024</chron></span> /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of <span>Takeda Pharmaceuticals, Inc.</span>, the R&amp;D-driven biopharmaceutical company headquartered in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.</p> <p>Following the completion of in vitro proof of concept studies of a novel plasma-derived therapy formulation, Nanoform will provide non-GMP nanomaterial to Takeda for <i>in vivo </i>studies. The first results of these studies are expected by early 2025.</p> <p>"Direct http://www.streetinsider.com/PRNewswire/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html Thu, 15 Aug 2024 01:37:00 -0400 A.39820687 NANOFH NANOFS O.00610135 http://www.streetinsider.com/PRNewswire/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/fi..helsin" idsrc="xmltag.org" >HELSINKI</location></span>, <span class="legendSpanClass"><chron>Aug. 15, 2024</chron></span> /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of <span>Takeda Pharmaceuticals, Inc.</span>, the R&amp;D-driven biopharmaceutical company headquartered in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.</p> <p>Following the completion of in vitro proof of concept studies of a novel plasma-derived therapy formulation, Nanoform will provide non-GMP nanomaterial to Takeda for <i>in vivo </i>studies. The first results of these studies are expected by early 2025.</p> <p>"Direct http://www.streetinsider.com/PRNewswire/NANOFORM+COLLABORATES+WITH+TAKEDA+ON+THEIR+PLASMA-DERIVED+THERAPY+DEVELOPMENT/23604668.html Thu, 15 Aug 2024 01:37:00 -0400 A.39820687 NANOFH NANOFS O.00610135